Proteinuria: Increased angiotensin-receptor blocking is not the first option

Piero Ruggenenti, Paolo Cravedi, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review


Candesartan doses in excess of the recommended antihypertensive maxima have been reported to lead to greater reductions of proteinuria than the advised doses. high-dose angiotensin-converting-enzyme inhibitors, however, are at least as effective as high-dose angiotensin blockers and less expensive. angiotensin-converting-enzyme inhibition is thus the first-line strategy to halt kidney disease progression.

Original languageEnglish
Pages (from-to)367-368
Number of pages2
JournalNature Reviews Nephrology
Issue number7
Publication statusPublished - Jul 2009

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)


Dive into the research topics of 'Proteinuria: Increased angiotensin-receptor blocking is not the first option'. Together they form a unique fingerprint.

Cite this